# **Regimen Reference Order – GENU - degarelix**

Planned Course:	Single dose followed by LHRH agonist therapy
	OR
	Loading dose followed by maintenance doses every 28 days until disease progression
Indication for Use:	Prostate Cancer

CVAD: Not Required

Proceed	l with	treatment i	f:
---------	--------	-------------	----

Not Applicable

## SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements				
Drug	Dose	CCMB Administration Guideline		
	٦	Not Applicable		

	Treatment Re	egimen – GENU - degarelix	
Drug	Dose	CCMB Administration Guideline	
degarelix (Firmagon®)	240 mg Single dose	Subcutaneous injection once (as two injections of 120 mg) into abdomen	
		*Nursing Alert: refer to package insert for reconstitution and administration instructions	
	OR		
	240 mg Loading dose	Subcutaneous injection (as two injections of 120 mg) into the abdomen, followed by maintenance doses to start one month later *Nursing Alert: refer to package insert for reconstitution and	
	80 mg Maintenance dose	administration instructions         Subcutaneous injection (as a single injection of 80 mg) every 28 days	
		*Nursing Alert: refer to package insert for reconstitution and administration instructions	

### **REQUIRED MONITORING**

At each clinic visit (at a minimum every 3 months)

• PSA and testosterone as per physician order



Recommended Support Medications				
Drug	Dose	CCMB Administration Guideline		
		Not Applicable		

#### **DISCHARGE INSTRUCTIONS**

• N/A

#### **ADDITIONAL INFORMATION**

• degarelix does not cause testosterone surges. There is no need for use of antiandrogens to prevent disease flare

